Herbas VPB

Print
EN | LT
LT - VMAT2 inhibitorius valbenazinas, skirtas panaudoti taikant pacientui, sergančiam sunkiu inkstų nepakankamumu, neurologinio arba psichiatrinio sutrikimo gydymo būdą
EN - THE VMAT2 INHIBITOR VALBENAZINE FOR USE IN A METHOD OF TREATING A NEUROLOGICAL OR PSYCHIATRIC DISORDER IN PATIENTS WITH SEVERE RENAL IMPAIRMENT

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. A61K 31/4738 (2006.01)
A61P 13/12 (2006.01)
A61P 25/00 (2006.01)
A61P 25/14 (2006.01)
A61P 25/16 (2006.01)
A61P 25/24 (2006.01)
A61P 25/28 (2006.01)
A61K 9/00 (2006.01)
European patent
(11) Number of the document 4017494
(13) Kind of document T
(96) European patent application number 20764910.4
Date of filing the European patent application 2020-08-21
(97) Date of publication of the European application 2022-06-29
(45) Date of publication and mention of the grant of the patent 2025-08-20
(46) Date of publication of the claims translation 2025-10-27
PCT application
(86) Number PCT/US2020/047392
Date 2020-08-21
PCT application publication
(87) Number WO 2021/041208
Date 2021-03-04
Priority applications
(30) Number Date Country code
201962890697 P 2019-08-23 US
202063028754 P 2020-05-22 US
Inventors
(72)
LOEWEN, Gordon Raphael , US
LUO, Sha Rosa , US
Grantee
(73) Neurocrine Biosciences, Inc. , 6027 Edgewood Bend Court, San Diego, CA 92130, US
Attorney or representative
(74) Jurga PETNIŪNAITĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Title
(54) VMAT2 inhibitorius valbenazinas, skirtas panaudoti taikant pacientui, sergančiam sunkiu inkstų nepakankamumu, neurologinio arba psichiatrinio sutrikimo gydymo būdą
  THE VMAT2 INHIBITOR VALBENAZINE FOR USE IN A METHOD OF TREATING A NEUROLOGICAL OR PSYCHIATRIC DISORDER IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
Last renewal fee
Payment date Validity (years) Amount
2025-08-25 6 139.00 EUR
Next renewal fee
2026-08-21